Ralexar Therapeutics

About:

Ralexar Therapeutics focuses on the development of an innovative portfolio of liver X receptor agonists.

Top Investors: Third Point Ventures, New Science Ventures

Description:

Ralexar Therapeutics company is developing topical and systemic therapies based on the Liver X Receptor (LXR) modulators. The initial focus for the company is on the clinical development of ALX-101, a topical LXR-based therapy, for the treatment of various cutaneous inflammatory disorders, including atopic dermatitis. Alexar changes its name to Ralexar Therapeutics. The company was founded in 2013 and is based in Malvern, Pennsylvania.

Total Funding Amount:

$41.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Malvern, Pennsylvania, United States

Founded Date:

2013-01-01

Contact Email:

info(AT)ralexar.com

Founders:

Raju Mohan

Number of Employees:

1-10

Last Funding Date:

2017-06-06

IPO Status:

Private

Industries: